Abstract | PURPOSE: PATIENTS AND METHODS: Thirty patients with clinical stage II or higher renal masses, selected based on their candidacy for nephrectomy, underwent preoperative treatment with sorafenib. Toxicities, surgical complications, and tumor responses were monitored. RESULTS: Of the thirty patients enrolled, 17 patients had localized disease and 13 had metastatic disease. After a course of sorafenib therapy (median duration, 33 days), a decrease in primary tumor size (median, 9.6%) and radiographic evidence of loss of intratumoral enhancement, quantified using a methodology similar to Choi criteria (median, 13%), was also observed. According to Response Evaluation Criteria in Solid Tumors, of the 28 patients evaluable for response, two patients had a partial response and 26 had stable disease, with no patients progressing on therapy. Toxicities from sorafenib were similar to that expected with this class of medication. All patients were able to proceed with nephrectomy and no surgical complications related to sorafenib administration were observed. CONCLUSION:
|
Authors | C Lance Cowey, Chirag Amin, Raj S Pruthi, Eric M Wallen, Matthew E Nielsen, Gayle Grigson, Cathy Watkins, Keith V Nance, Jeffrey Crane, Mark Jalkut, Dominic T Moore, William Y Kim, Paul A Godley, Young E Whang, Julia R Fielding, W Kimryn Rathmell |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 28
Issue 9
Pg. 1502-7
(Mar 20 2010)
ISSN: 1527-7755 [Electronic] United States |
PMID | 20159822
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Benzenesulfonates
- Phenylurea Compounds
- Pyridines
- Niacinamide
- Sorafenib
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(administration & dosage)
- Benzenesulfonates
(administration & dosage)
- Carcinoma, Renal Cell
(drug therapy, pathology)
- Feasibility Studies
- Female
- Humans
- Kidney Neoplasms
(drug therapy, pathology)
- Male
- Middle Aged
- Neoadjuvant Therapy
- Neoplasm Staging
- Niacinamide
(analogs & derivatives)
- Phenylurea Compounds
- Pilot Projects
- Prospective Studies
- Pyridines
(administration & dosage)
- Sorafenib
- Treatment Outcome
- Young Adult
|